Fig. 3

Response status of AG-resistant PDAC with K-80003 treatment from in-house and external cohorts. A, Flow chart for screening PDAC patients for K80003 sensitization AG regimen. B, Complex heatmap showing distribution of clinical parameters between in-house cohort and external cohort of AG-resistant PDAC. C, Kaplan–Meier overall survival (PFS) curves between in-house cohort and external cohort of AG-resistant PDAC. D, Representative HE staining images of 12 AG-resistant PDAC samples and PODs from in-house cohort, and ability of K-80003 to sensitize samples to AG chemotherapy. E, Weight of tumors from mice in the different groups (5 mice per group), and survival curves for mice that received different treatments (5 mice per group). Tumors from different groups of PDOXs received different treatments from weeks 2 after orthotopic xenograft injection of 1 million corresponding PDOs. Mice were treated with saline, the dual combination of gemcitabine (25 mg/kg, weekly), and nab-paclitaxel (15 mg/kg, weekly; red arrows), or the triple combination of gemcitabine and nab-paclitaxel (as dosed for the monotherapies) plus K-80003 (20 mg/kg, twice weekly; blue arrows) for 3 weeks. Tumors were harvest at 3 weeks after treatment. Survival curves for mice that received different treatments (5 mice per group). F, Representative HE staining images of 11 AG-resistant PDAC-derived PDOs in external cohort, and ability of K-80003 to sensitize them to AG chemotherapy. G, Weight of tumors from mice in the different groups (5 mice per group), and survival curves for mice that received different treatments (5 mice per group). Not significant (ns), *P <0.05; **P < 0.01; ***P < 0.001